Literature DB >> 31470931

Novel Target Selection for Nuclear Medicine Studies.

Sze Ting Lee1, I Burvenich2, A M Scott3.   

Abstract

Nuclear medicine techniques involving SPECT and PET are being increasingly used as a noninvasive tool for the detection, quantitation and therapy response monitoring of a myriad of disease processes through target visualization and kinetic modeling. The target selection requires a good understanding of the physiologic changes involved in the disease processes. The target selected can range from cellular proteins expressed in a particular organ, biochemical pathways in cells, or receptors on circulating blood cells. This can have a significant impact on therapeutic options for subsequent therapies, including radionuclide therapies in this evolving world of theranostic practices, which is outlined in this review.
Copyright © 2019. Published by Elsevier Inc.

Mesh:

Substances:

Year:  2019        PMID: 31470931     DOI: 10.1053/j.semnuclmed.2019.06.004

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  5 in total

Review 1.  Radiotheranostics: a roadmap for future development.

Authors:  Ken Herrmann; Markus Schwaiger; Jason S Lewis; Stephen B Solomon; Barbara J McNeil; Michael Baumann; Sanjiv S Gambhir; Hedvig Hricak; Ralph Weissleder
Journal:  Lancet Oncol       Date:  2020-03       Impact factor: 41.316

Review 2.  Radiotheranostics in oncology: current challenges and emerging opportunities.

Authors:  Lisa Bodei; Ken Herrmann; Heiko Schöder; Andrew M Scott; Jason S Lewis
Journal:  Nat Rev Clin Oncol       Date:  2022-06-20       Impact factor: 65.011

3.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

Review 4.  The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis.

Authors:  Javier Muñoz-Garcia; Denis Cochonneau; Stéphane Télétchéa; Emilie Moranton; Didier Lanoe; Régis Brion; Frédéric Lézot; Marie-Françoise Heymann; Dominique Heymann
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 5.  A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Authors:  Julie Bolcaen; Janke Kleynhans; Shankari Nair; Jeroen Verhoeven; Ingeborg Goethals; Mike Sathekge; Charlot Vandevoorde; Thomas Ebenhan
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.